[SCHEDULE 13G/A] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 1 to Schedule 13G for Astera Labs Inc. (ALAB) with an event date of 06/30/2025.

Key ownership data:

• Beneficially owned shares: 12,049,223
• Percent of class: 7.3 %
• Sole voting power: 0
• Shared voting power: 69,540
• Sole dispositive power: 11,858,240
• Shared dispositive power: 190,983

Vanguard is classified as an investment adviser (IA) making a passive filing under Rule 13d-1(b). The firm certifies that the stake was acquired in the ordinary course of business and not to influence control of the issuer. Dividend and sale proceeds rights reside with Vanguard’s underlying clients, none of whom individually own more than 5% of the class.

Positive

• High-quality institutional holder: Vanguard’s 7.3 % passive stake introduces a well-regarded, long-term investor to the register, potentially boosting market confidence.

Negative

• Minimal governance influence: Vanguard reports zero sole voting power, limiting its ability to advocate for shareholder-friendly changes.

Insights

Securities Analyst

TL;DR: Vanguard's passive 7.3 % stake adds institutional sponsorship, but limited voting power means minimal governance impact; overall neutral-to-slightly-positive.

This 13G/A shows Vanguard controls 12.0 M ALAB shares, exceeding the 5 % disclosure threshold. The stake is sizable for a newly public company and may enhance liquidity and analyst coverage. However, Vanguard reports zero sole voting power and only 69.5 K shared votes, underscoring a purely passive position. Without an activist tilt or board influence, the filing has little immediate strategic implication. Market reaction is typically modest, yet long-only investors may view the presence of a respected index manager as validation of fundamentals.

Corporate Governance Expert

TL;DR: Filing confirms passive ownership; governance leverage negligible given 0% sole voting power—impact rated neutral.

Vanguard’s IA status and certification signal no intent to influence control. The absence of sole voting authority means management autonomy remains intact. From a governance lens, this reduces the likelihood of shareholder proposals or board nomination pressure from this holder. The filing primarily updates disclosure obligations rather than altering the power dynamic within Astera Labs. Consequently, governance risk profile remains unchanged.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Bridgebio Pharma Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

10806X102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 10806X102

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 186,259.00
7	Sole Dispositive Power 16,126,179.00
8	Shared Dispositive Power 358,806.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,484,985.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.68 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bridgebio Pharma Inc
(b)	Address of issuer's principal executive offices: 3160 Porter Dr, Suite 250, Palo Alto, CA, 94304
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 10806X102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 16484985
(b)	Percent of class: 8.68 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 186259
	(iii) Sole power to dispose or to direct the disposition of: 16126179
	(iv) Shared power to dispose or to direct the disposition of: 358806
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How many Astera Labs (ALAB) shares does Vanguard own?

The filing lists 12,049,223 common shares beneficially owned.

What percentage of ALAB’s outstanding shares does this represent?

Vanguard’s stake equals 7.3 % of the outstanding common stock.

Does Vanguard have voting control over the shares?

No. Vanguard reports 0 sole voting power and 69,540 shared votes, indicating limited influence.

Is Vanguard’s position passive or activist?

The Schedule 13G/A is a passive filing under Rule 13d-1(b); Vanguard certifies no intent to influence control.

When was the ownership threshold triggering this filing reached?

The event date prompting the amendment is 06/30/2025.